当前位置: X-MOL 学术Cell. Oncol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Association of DCBLD2 upregulation with tumor progression and poor survival in colorectal cancer.
Cellular Oncology ( IF 6.6 ) Pub Date : 2020-03-12 , DOI: 10.1007/s13402-020-00495-8
Jie He 1, 2, 3 , Hongli Huang 1, 2, 3 , Yanlei Du 1, 2, 3 , Dong Peng 1, 2, 3 , Youlian Zhou 1, 2, 3 , Yuyuan Li 1, 2, 3 , Hong Wang 1, 2, 3 , Yongjian Zhou 1, 2, 3 , Yuqiang Nie 1, 2, 3
Affiliation  

Purpose

DCBLD2 expression dysregulation has been reported in several types of human cancer. As yet, however, the role of DCBLD2 in colorectal cancer (CRC) is not known.

Methods

CRC tissues were obtained from patients undergoing surgery from February 2009 to May 2014 (n = 90). Tissue microarray construction and immunohistochemistry were carried out to determine DCBLD2 expression. In vivo studies were performed in 4-week-old BALB/c nude mice. In vitro studies were conducted using CRC-derived HT29 and HCT116 cell lines.

Results

DCBLD2 expression was found to be significantly increased in CRC tissues compared to adjacent normal tissues (p < 0.001). In addition, we found that DCBLD2 expression was positively correlated with the stage of the disease, the degree of differentiation and vascular invasion. High DCBLD2 expression was significantly associated with a poor overall survival. In vitro, DCBLD2 expression downregulation significantly reduced CRC cell proliferation and invasion. In a mouse xenograft model, DCBLD2 expression downregulation reduced lung metastasis and increased overall survival. Gene set enrichment analysis (GSEA) revealed that DCBLD2 overexpression induces epithelial–mesenchymal transition (EMT) and activates the JAK/STAT3 pathway.

Conclusions

We found that high DCBLD2 expression correlated with a poor clinical outcome, as well as tumorigenesis, invasion and metastasis of CRC cells. DCBLD2 may serve as a prognostic biomarker and a novel therapeutic target for CRC.


中文翻译:

DCBLD2上调与大肠癌肿瘤进展和不良生存的关系。

目的

在几种类型的人类癌症中已经报道了DCBLD2表达失调。然而,迄今为止,DCBLD2在结直肠癌(CRC)中的作用尚不清楚。

方法

CRC组织从2009年2月至2014年5月的手术患者中获得(n  = 90)。进行组织微阵列构建和免疫组织化学以确定DCBLD2表达。在4周龄的BALB / c裸鼠中进行了体内研究。使用CRC衍生的HT29和HCT116细胞系进行了体外研究。

结果

与邻近的正常组织相比,发现CRC组织中的DCBLD2表达显着增加(p  <0.001)。另外,我们发现DCBLD2表达与疾病的阶段,分化程度和血管侵袭呈正相关。DCBLD2高表达与不良的总生存率显着相关。在体外,DCBLD2表达下调显着降低了CRC细胞的增殖和侵袭。在小鼠异种移植模型中,DCBLD2表达下调减少了肺转移并增加了总生存期。基因集富集分析(GSEA)显示DCBLD2过表达诱导上皮-间质转化(EMT)并激活JAK / STAT3途径。

结论

我们发现高DCBLD2表达与不良的临床结果以及CRC细胞的肿瘤发生,侵袭和转移相关。DCBLD2可以作为CRC的预后生物标志物和新型治疗靶标。
更新日期:2020-03-12
down
wechat
bug